67 WALL STREET, New York - June 1, 2009 - The Wall Street Transcript has just published its Biotechnology Report report offering a timely review of the sector to serious investors and industry executives. This 107 page feature contains expert industry commentary through in-depth interviews. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. 

Topics covered: Negative financing environment - Regulatory outlook - R&D spending outlook - M&A activity - Potential acquisition targets - Big Pharma interest in acquisitions - FDA approval process - Missed PDUFA dates - Molecular diagnostics growth area - Follow-on biologics - Activist shareholder action - Cost containment measures - More generic drug usage - IPO window - Shortage of cash - Expectation of more bankruptcies - Winners and losers - Investor interest - Stocks picks 

Companies include: Genzyme (GENZ); Celgene (CELG); Gilead Sciences (GILD); Medivation (MDVN); Sequenom (SQNM); XenoPort (XNPT); ARYx Therapeutics (ARYX); Biogen Idec (BIIB); Dendreon (DNDN); Acorda Therapeutics (ACOR); Alexion (ALXN); Cardiome (CRME); Vertex Pharmaceuticals (VRTX); Avigen (AVGN); Amylin Pharmaceuticals (AMLN); Micromet (MITI); BioMarin Pharmaceuticals (BMRN); Myriad Genetics (MYGN). 

In the following brief excerpt from the 107 page report, the CEO of Nuvilex discusses his company's hangover remedy. 

TWST: What are your priorities for Nuvilex? What will make the next 12 to 24 months successful for the company? 

Mr. Schmieg: In a single word, performance. We need to instill a new level of confidence in our investors through performance - setting and achieving our goals. Our initial performance milestone will be in topside revenue growth, which we have given guidance of between $3 million and $5 million for the current fiscal year that runs from May 1, 2009 through April 30, 2010. In the near term, we will be launching our Last Shot Hangover Remedy, a safe and novel blend of essential minerals and nutrients developed to help the body metabolize the sugar in alcohol, thereby preventing or minimizing a hangover. The preventative hangover remedy is packaged in a two-ounce tube and it is meant to be taken in one shot, followed by 16 ounces of water, before going to sleep. Following a successful spring break initiative to market Last Shot along with our InfinitInk, we have seen positive reactions among the key 18 to 25 year-old demographic group. We believe that the product has the potential to make significant revenue contributions. 

TWST: Would you give us some insight into your technology platform as well as the lead products that you have under development? 

Mr. Schmieg: There are various technology platforms. They include a technology we call P2E, which is an encapsulation technology for developing safe tattoo inks and can also be used for drug delivery. The second is Cinnergen. Cinnergen is our supplement formula that is engineered to help pre-diabetics and diabetics manage their metabolism. Cinnergen has now become a family of products that includes Cinnergen itself; Cinnechol, a supplement to support good cardiovascular health, and two new products. The first is our Last Shot Hangover Remedy, which is a product taken at the end of a night of imbibing and it will eliminate or nearly eliminate all of your hangover symptoms the next morning. The other is Prevorex, an appetite aid to help those who are either on diets or trying to control their calorie intake. Our third technology is Citroxin, which starts as an eco-friendly cleaner that is highly effective as a germicide and antiviral surface cleaner. Citroxin is also being developed as a nematicide and a homeopathic medicine. 

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 107 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online . 

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673

About Nuvilex, Inc.
Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Investor Relations Contacts:

Blair Barnes
Senior Vice President and Chief Financial Officer
Nuvilex, Inc.
Ph: 856-433-6088
Email: bbarnes@nuvilex.com

Stephanie Carrington/Amy Glynn
The Ruth Group
Ph: 646-536-7017/7023
Email: scarrington@theruthgroup.com
Email: aglynn@theruthgroup.com

Press Contact:

Pat Arcand
Arcand & Madison
Ph: 617-576-7777
Email: pat@am-pr.com